Amy B. Sullivan, PsyD


Amy B. Sullivan, PsyD: Screening MS Patients for Comorbidities

The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the importance of screening patients with MS for other conditions for which they are prevalently comorbid, such as depression or sleep disorders.

Peter J. Goadsby, MD, PhD, DSc


Impressive Response Rates for Patients in Migraine Prevention Study: Peter J. Goadsby, MD, PhD, DSc

The professor of neurology at King’s College, London, spoke about the phase 3 ELEVATE trial investigating atogepant for episodic migraine at the 2023 AAN Annual Meeting. [WATCH TIME: 5 minutes]

Kathryn A. Davis, MD, FAES


Using Artificial Intelligence Applications in Neurology to the Field: Kathryn A. Davis, MD, MSc

The associate professor of neurology and director of the Penn Epilepsy Center at the University of Pennsylvania talked about the potential of using artificial intelligence in the field of neurology as part of an upcoming session at the 2023 AAN annual meeting. [WATCH TIME: 5 minutes]

Anthony Traboulsee, MD, FRCPC


The Importance of a Globally Aligned, Standardized MRI Protocol for MS

Leaders of the CMSC Working Group on MRI protocols and clinical guidelines express the need for a unified approach to diagnosing and monitoring multiple sclerosis.

John L. Berk, MD


Future Treatment of hATTR Amyloidosis

Analysis of current and newer therapies for the treatment of hereditary ATTR amyloidosis.

Lutz Frolich, MD, PhD


Lutz Frolich, MD, PhD: Learning from Negative Trials

Lutz Frölich, MD, PhD, spoke about the importance of continuing with research in light of negative trials in Alzheimer disease.

James A. Charles, MD, FAAN, FAHS


Justifying Use of CGRP mAbs in Pediatric Patients With Migraine

What happens to the approximately 24% of pediatric patients with migraine who do not respond to the preventive treatments recommended in the AAN guidelines?

Jacqueline French, MD


Jacqueline French, MD: Barriers to Identifying Nonmotor Seizures

The director of Translational Research and Clinical Trials Epilepsy at NYU Grossman School of Medicine discussed the need to improve education about nonmotor seizures.

Amit Rakhit, MD, MBA


Amit Rakhit, MD, MBA: Measuring Improvement in Fragile X Syndrome, Other Rare Conditions

The chief medical officer and head of Research & Development at Ovid Therapeutics spoke about what prompted the development of this scale to measure improvement for patients with Fragile X syndrome, and possibly other conditions.

Andre Machado, MD, PhD


Andre Machado, MD, PhD: Multidisciplinary Treatment in Movement Disorders

The Chairman of the Neurological Institute at Cleveland Clinic provided insight into the multidisciplinary decision-making process for patients with movement disorders at the center.

Trevor J. Resnick, MD


Therapies for Children and Adults with Dravet Syndrome

The panelists discuss the possibility of treating Dravet syndrome in older children and adults and the effects if the therapies were effective.  

Matthew B. Harms, MD


The Development of New Gene Therapies to Address Unmet Needs in ALS: Matthew B. Harms, MD

The associate professor of neurology at Columbia University spoke at the 2023 MDA conference about the unmet needs of patients with ALS and the potential of new gene therapies. [WATCH TIME: 5 minutes]

Ronald Witteles, MD


Future Treatment of hATTR Amyloidosis

Analysis of current and newer therapies for the treatment of hereditary ATTR amyloidosis.

Eric Segal, MD


2020 Epilepsy Review: Much to Be Excited About

Despite 2020 being a challenging year for those in medicine, the epilepsy therapeutic space featured a number of key steps forward.

Hideki Garren, MD, PhD


Hideki Garren, MD, PhD: Measuring MS Progression With Floodlight Open

The smartphone application-led program, Floodlight Open, recently initiated in the US and Canada.

Kenny Walter


Robert Califf, MD, Nominated by Biden Administration as Next FDA Commissioner

Having previously served as head of the organization during the Obama administration, Califf will replace current Acting Commissioner Janet Woodcock, MD.

Davangere Devanand, MBBS, MD


Davangere Devanand, MBBS, MD: Challenges in Symptom Management in Alzheimer Disease

Davangere P. Devanand, MBBS, MD, discussed the possibility of neurologists prescribing low-dose lithium for patients with Alzheimer and symptoms of agitation.

James Kupiec, MD


Aducanumab Reinvigorates the Fight Against Alzheimer Disease

The chief medical officer of ProMIS Neurosciences comments on how aducanumab will help propel innovation needed to drive the next generation of therapies for Alzheimer disease.

Anli Liu, MD


Anli Liu, MD: Responsive Neurostimulation System for Cognition in Epilepsy

Liu discussed this work and the findings of this proof-of-principle trial in memory in epilepsy.

Scott Newsome, DO, MSCS, FAAN


Novel and Emerging Targets in Multiple Sclerosis

Experts in neurology share their hopes for the future of multiple sclerosis treatment and discuss unmet needs and novel targets.

Johan Verbraecken, MD, PhD


Johan Verbraecken, MD, PhD: Challenges in Conducting Clinical Trials in OSA

The medical coordinator of the Multidisciplinary Sleep-Wake Disorders Center at Antwerp University Hospital spoke about how to address some of the issues faced in OSA treatment development.

Zhibin Chen, PhD


Zhibin Chen, PhD: Treatment Gap in Patients with Newly Diagnosed Epilepsy

Despite accessibility to antiepileptic drugs in high-income settings, more than one-third of patients with newly diagnosed epilepsy were not treated or had delayed treatment.

Shimrit Uliel-Sibony, MD


Shimrit Uliel-Sibony, MD: Can Patients Develop a CBD Tolerance?

Uliel-Sibony discussed her and her colleagues' study of CBD, and its findings on when tolerance develops for which patient population.

Trevor Resnick, MD


Trevor Resnick, MD: Treating Epilepsy By Blending Technology, Genetics, and Pharmacologics

The pediatric epileptologist at Nicklaus Children’s Hospital spoke about the future of epilepsy and shared which studies of the condition that he’s been keeping an eye on.

Asher J. Albertson, MD, PhD


Asher J. Albertson, MD, PhD: Getting Interventions to Stroke Patients

Albertson discussed this facet of stroke care, and all the things being done outside just the clinic to help improve outcomes.

Pascal Sati, PhD


The Future of Multiple Sclerosis Imaging

Advanced imaging technology collides with artificial intelligence in what is shaping up to be a revolutionary period for the diagnosis and management of MS.

Joseph Sullivan, MD


Shift in Treatment Paradigm for Dravet Syndrome: Joseph Sullivan, MD

The director of the Pediatric Epilepsy Center at UCSF provided perspective on the advances in the treatment of Dravet syndrome, emerging research concepts in the field, and the influence of genetic testing. [WATCH TIME: 5 minutes]

© 2023 MJH Life Sciences

All rights reserved.